Hopital Paul Brousse — Clinical Trial Site

48 Registered trials

26 Currently recruiting

Organisation

Hopital Paul Brousse

Location

Villejuif Cedex, France

Identifier

ORG-100028436

Address

12 Avenue Paul Vaillant Couturier, 94804, France

Departments

2303: Centre Hépato-Biliaire
2313: Oncology
94804
Centre hapato-biliaire
Centre Hépato Bilaire
Centre Hépato-Biliaire
Centre Hépatobiliare
Chirurgie Viscérale et Digestive
Digestive and medical Oncology
Gastro entérologie et Hépatologie
Gastro-enterology and Hepatology department
Gastroenterology
Hématologie
Hepato-biliary Centre
Hépato-Gastroentérologie
Hepatobiliary
Hepatologie
Hepatology
Hepatology department
Médical Oncology
Oncologie digestive et médicale
Oncology
Psychiatrie
Psychiatry
Service Centre d’Hépato-Biliaire
Service d’hépatologie et transplantation hépatique
Service Gastro-entérologie et Hépatologie
Service oncologie digestive
Service oncologie digestive et medicale
Surgery
Val-de-Marne
Visceral and digestive surgery

Clinical trials at this site (48)

Search interface

Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas… Recruiting

2023-506753-38-00 metastatic gastric adenocarcinoma 4 2024-04-16
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting

2023-505251-43-00 Primary Biliary Cholangitis 5 2024-02-28
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma… Recruiting

2022-501943-34-00 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease 5 2023-06-27
NAlmefene versus placebo in addition to treatment as usual on craving in Behavioural Addictions (NABAb) Recruiting

2022-500085-96-00 Patients with gambling disorder or sexual addiction or 5 2023-03-31
TERTIO : Evaluation de l’intérêt de combiner un vaccin inducteur de CD4-Th1 dérivé de la télomérase avec un traitement par atezolizumab et b… Recruiting

2022-500643-20-00 Patients with locally advanced, metastatic or unresecta 4 2022-09-27
A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholan… Recruiting

2023-504660-41-00 Cholestatic Pruritus in Patients with Primary Biliary C 4 2022-07-11
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting

2024-512982-15-00 BRCA Mutated Ovarian Cancer Patients, Epithelian ovaria 5 2021-06-28
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cance… Recruiting

2024-515344-23-00 local advenced pancreatic adenocarcinoma 4 2021-06-17
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended

2024-516063-89-00 Metastatic Pancreatic Ductal Adenocarcinoma 5 2025-04-10
PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first… Ended

2024-518553-41-00 colon cancer and rectal with liver metastasis 5 2024-11-08
A Study of Elafibranor in Adults with Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid Ended

2024-510695-20-00 Primary Biliary Cholangitis (PBC) 5 2024-10-15
A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended

2023-506054-20-00 Adenocarcinoma of the biliary tract (intrahepatic or ex 5 2024-06-05
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati… Ended

2022-502043-35-01 Advanced Biliary Tract Cancers 5 2024-04-24
A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He… Ended

2023-503422-39-00 Hepatocellular Carcinoma (HCC) 5 2023-10-20
A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T… Ended

2023-508945-41-00 Hepatocellular Carcinoma 4 2023-10-11
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended

2024-510627-20-00 Non-alcoholic Steatohepatitis (NASH) Cirrhosis 5 2023-07-28
A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended

2023-508248-23-00 Non-alcoholic steatohepatitis (NASH) 5 2021-11-26
Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HC… Ended

2023-508635-31-00 Hepatocellular Carcinoma 5 2019-12-03
A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Res… Ended

2023-508726-10-00 Hepatocellular Carcinoma 5 2018-03-28
A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C… Ended

2022-502840-11-00 Hepatocellular Carcinoma (Morpheus-Neo HCC) 9 2023-11-28
Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma Ended

2022-502116-36-00 Incurable/Non-metastatic Hepatocellular Carcinoma 5 2020-07-10
Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality Ended

2022-502187-20-00 Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3 5 2019-04-11
PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStem Ended

2022-500251-22-00 This study will include all patients having received at 4 2018-04-12